Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06531941 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
A Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06531941: Active Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.
NCT06531941 is a Phase 2 study of Hypoparathyroidism that is active but no longer recruiting, run by MBX Biosciences. The registered enrollment target is 60 participants, below the 194-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06531941, a Phase 2 study of Hypoparathyroidism, is active but no longer recruiting, sponsored by MBX Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
Conditions Studied
Interventions
- DRUG 400 µg of MBX 2109 once-weekly by subcutaneous injection
- DRUG 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Study Locations (20)
Texas
- MBX Biosciences Investigational Site - Dallas
- MBX Biosciences Investigational Site - El Paso
- MBX Biosciences Investigational Site - Fort Worth
- MBX Biosciences Investigational Site - Round Rock
- MBX Biosciences Investigational Site - San Antonio
- MBX Biosciences Investigational Site - Weslaco
New York
- MBX Biosciences Investigational Site - Albany
- MBX Biosciences Investigational Site - New York
- MBX Biosciences Investigational Site - The Bronx
Nevada
- MBX Biosciences Investigational Site - Las Vegas
- MBX Biosciences Investigational Site - Reno
Buenos Aires
- MBX Biosciences Investigational Site - Ciudad Autonoma de Buenos Aires
- MBX Biosciences Investigational Site - Ciudad Autonoma de Buenos Aires
Florida
- MBX Biosciences Investigational Site - Miami
Georgia
- MBX Biosciences Investigational Site - Macon
Mississippi
- MBX Biosciences Investigational Site - Jackson
Missouri
- MBX Biosciences Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2027-05-27 |
| Phase | Phase 2 |
What the registry record for NCT06531941 still lists
NCT06531941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 194-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which 400 µg of MBX 2109 once-weekly by subcutaneous injection is the first listed.
NCT06531941 names 20 study sites across 11 states, led by Texas, New York, Nevada.
Frequently Asked Questions
What is clinical trial NCT06531941 about?
NCT06531941 is a clinical study titled "Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism". The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
What is the current status of trial NCT06531941?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-10-31. Estimated completion is 2027-05-27.
What conditions does trial NCT06531941 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT06531941?
The interventions under investigation include: 400 µg of MBX 2109 once-weekly by subcutaneous injection (DRUG), 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT06531941?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06531941 being conducted?
This trial has 20 study locations across Florida, Georgia, Mississippi, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06531941's enrollment target sits among peer trials
60 7th of 10 higher than 4 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
COMPLETED · Phase 2
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI